Immuron Ltd (NASDAQ:IMRN, ASX:IMC) chief commercial officer Flavio Palumbo speaks with Proactive following the news its Travelan product has launched on Amazon US.

Travelan is known to protect against the onset of travellers’ diarrhea (TD), the most common illness reported by travellers.

By launching directly onto Amazon US he says it gives consumers across the US the convenience to purchase Travelan with the ease of a click.

In other news, Immuron recently announced it has enrolled the first cohort of 30 participants into its Travelan® clinical study.

This Phase 2 trial aims to test Travelan®'s safety and its ability to protect against infection, compared to a placebo, in a controlled human infection model.

It is also examining a dosing regimen for Travelan® more suited to the US military.

Dosing should complete early next month, with headline results from the clinical trial expected in the first half of 2024.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com